Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) FCF Margin (2016 - 2025)

Agios Pharmaceuticals' FCF Margin history spans 13 years, with the latest figure at 501.79% for Q4 2025.

  • For Q4 2025, FCF Margin rose 75441.0% year-over-year to 501.79%; the TTM value through Dec 2025 reached 698.33%, up 37440.0%, while the annual FY2025 figure was 698.33%, 37440.0% up from the prior year.
  • FCF Margin reached 501.79% in Q4 2025 per AGIO's latest filing, up from 686.06% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 501.79% in Q4 2025 to a low of 12084.01% in Q1 2022.
  • Average FCF Margin over 4 years is 1809.98%, with a median of 1115.03% recorded in 2024.
  • Peak YoY movement for FCF Margin: surged 1037993bps in 2023, then plummeted -24568bps in 2024.
  • A 4-year view of FCF Margin shows it stood at 1537.73% in 2022, then surged by 34bps to 1010.53% in 2023, then fell by -24bps to 1256.21% in 2024, then soared by 60bps to 501.79% in 2025.
  • Per Business Quant, the three most recent readings for AGIO's FCF Margin are 501.79% (Q4 2025), 686.06% (Q3 2025), and 614.05% (Q2 2025).